好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Feasibility and Validity of an Interdepartmental Diagnostic Pathway to Risk-Stratify Youths presenting to the Emergency Department with First-Episode Psychosis according to Likelihood of a Neuroimmunologic Etiology
Autoimmune Neurology
P3 - Poster Session 3 (12:00 PM-1:00 PM)
003

To validate an emergency room (ER) pathway that risk-stratifies youths with first-episode psychosis (FEP) according to the likelihood of secondary etiologies, inclusive of autoimmune encephalitis (AE), and guides evaluation for low and high-risk patients.

Rates of ER visits for psychosis are rising at alarming rates, particularly among youths. Rarely, psychosis is the sole presenting feature of AE. While early AE detection and treatment are critical, invasive testing and overdiagnosis can lead to harm. There is thus a growing need for tools to differentiate between FEP due to primary psychiatric versus secondary neuroimmunologic causes in the acute care setting.

An interdepartmental pathway was developed through collaboration between our neurology, psychiatry and emergency departments. Patients under 22 years old presenting to the ER with FEP were prospectively enrolled. Pathway entry required FEP verification by psychiatry. Enrolled patients were risk-stratified according to the presence or absence of predetermined red-flag signs and results of initial tests: brain magnetic resonance imaging and serum studies. The pathway directed the role and timing of neurologic consultation and additional evaluation (including lumbar puncture [LP] and electroencephalogram [EEG]) according to level of risk.

Thirty-five patients were prospectively enrolled over a 19-month period. Nineteen (54%) had atypical psychiatric symptoms. Brain MRI and serum AE panels were performed in 33 (94%) and 29 (83%) of patients respectively, but none of these findings were clinically significant. Per the pathway’s algorithm, none of the enrolled patients required an LP or EEG. None were found to have a neuroimmunologic or other secondary etiology of FEP (negative predictive value = 100%).

To our knowledge, this is the first interdepartmental diagnostic algorithm used in practice to triage youths with psychiatrist-confirmed FEP in the ER setting. Feasibility, validity and clinical utility were demonstrated.

Authors/Disclosures
Mattia Wruble, MD
PRESENTER
The institution of Dr. Wruble has received research support from Alexion. The institution of Dr. Wruble has received research support from Roche.
Leah L. Wibecan, MD, MPH Dr. Wibecan has nothing to disclose.
Abigail Donovan No disclosure on file
Jenny Linnoila, MD, PhD (University Neurology Associates, UPMC) Dr. Linnoila has received personal compensation in the range of $10,000-$49,999 for serving as a expert respondent on autoimmune encephalitis with U.S. government/DHHS/Vaccine Injury Compensation Program.
Ashley Foster (University of California, San Francisco) No disclosure on file
Jessica Becker, MD An immediate family member of Dr. Becker has received personal compensation for serving as an employee of SmartLabs. An immediate family member of Dr. Becker has stock in Second Lab, LLC. The institution of Dr. Becker has received research support from American Academy of Child and Adolescent Psychiatry and Industry Sponsors.
Giovanna Manzano, MD Dr. Manzano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gilead Sciences. Dr. Manzano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for InfuCare Rx.